About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

NCT00706537·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pfizer

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Body Mass Index (BMI) of 25 to 40 kg/m2
Subjects with biopsy evidence of NASH in the 2 years prior to the screening visit.
Hemoglobin ≥11 g/dL, platelet count ≥100,000 cells/mm3, neutrophil count ≥1,500cells/mm3.

You may not be if

Other forms than NASH liver disease.
Decompensated or severe liver disease.

The record

StatusCompleted

PhasePhase 1

Taking part9

StartedJul 2008

UpdatedAug 13, 2009

Conditions

Non-Alcoholic Steatohepatitis(NASH)

Where3

Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Durham, North Carolina, United States

Clareo Health | Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH